methyl 4-((1-phenethyl-3-phenylureido)methyl)benzoate | 1421842-66-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-((1-phenethyl-3-phenylureido)methyl)benzoate
• 英文别名: Methyl 4-[[phenylcarbamoyl(2-phenylethyl)amino]methyl]benzoate；methyl 4-[[phenylcarbamoyl(2-phenylethyl)amino]methyl]benzoate
• CAS: 1421842-66-1
• 化学式: C₂₄H₂₄N₂O₃
• 分子量: 388.466
• InChiKey: XLTKQZVFWKFGAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 4-((1-phenethyl-3-phenylureido)methyl)benzoate 在 羟胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 0.5h， 以63%的产率得到N-hydroxy-4-((1-phenethyl-3-phenylureido)methyl)benzamide
  参考文献：
  名称：

  Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth

  摘要：

  The incidence of malignant melanoma has dramatically increased in recent years thus requiring the need for improved therapeutic strategies. In our efforts to design selective histone deactylase inhibitors (HDACI), we discovered that the aryl urea 1 is a modestly potent yet nonselective inhibitor. Structure-activity relationship studies revealed that adding substituents to the nitrogen atom of the urea so as to generate compounds bearing a branched linker group results in increased potency and selectivity for HDAC6. Compound 5g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of similar to 600-fold relative to the inhibition of HDACI. These HDACIs were evaluated for their ability to inhibit the growth of B16 melanoma cells with the most potent and selective HDAC6I being found to decrease tumor cell growth. To the best of our knowledge, this work constitutes the first report of HDAC6-selective inhibitors that possess antiproliferative effects against melanoma cells.

  DOI：

  10.1021/jm301098e
• 作为产物：
  描述：

  对甲酰基苯甲酸甲酯 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 32.0h， 生成 methyl 4-((1-phenethyl-3-phenylureido)methyl)benzoate
  参考文献：
  名称：

  Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth

  摘要：

  The incidence of malignant melanoma has dramatically increased in recent years thus requiring the need for improved therapeutic strategies. In our efforts to design selective histone deactylase inhibitors (HDACI), we discovered that the aryl urea 1 is a modestly potent yet nonselective inhibitor. Structure-activity relationship studies revealed that adding substituents to the nitrogen atom of the urea so as to generate compounds bearing a branched linker group results in increased potency and selectivity for HDAC6. Compound 5g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of similar to 600-fold relative to the inhibition of HDACI. These HDACIs were evaluated for their ability to inhibit the growth of B16 melanoma cells with the most potent and selective HDAC6I being found to decrease tumor cell growth. To the best of our knowledge, this work constitutes the first report of HDAC6-selective inhibitors that possess antiproliferative effects against melanoma cells.

  DOI：

  10.1021/jm301098e

文献信息

• [EN] PREPARATION AND USE OF BICYCLIC HIMBACINE DERIVATIVES AS PAR-RECEPTOR ANTAGONISTS<br/>[FR] PRÉPARATION ET UTILISATION DE DÉRIVÉS BICYCLIQUES D'HIMBACINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE PAR
  申请人：MERCK SHARP & DOHME

  公开号：WO2013134012A1

  公开（公告）日：2013-09-12

  The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: X is -O-, -N(R), -C(R8)(R9) or -C(O)-; and Y is -O-, -N(R), -C(R8)(R9) or -C(O)- and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ACS, secondary prevention of myocardial infarction or stroke, or PAD.

  本发明涉及公式的双环希巴辛衍生物或其药用可接受盐，其中：X为-O-，-N(R)，-C(R8)(R9)或-C(O)-；Y为-O-，-N(R)，-C(R8)(R9)或-C(O)-，其余变量如本文所述。本发明的化合物是PAR-1受体的有效抑制剂。这些创新化合物可用于治疗或预防疾病状态，如急性冠状综合征（ACS），心肌梗死或中风的二级预防，或PAD。
• [EN] SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS D'HISTONE DÉSACÉTYLASE 6
  申请人：H LEE MOFFITT CANCER CT & RES

  公开号：WO2013134467A1

  公开（公告）日：2013-09-12

  Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

  披露了具有化学式（I）的选择性组蛋白去乙酰化酶抑制剂（HDACi）。还披露了制备和使用这些抑制剂用于治疗癌症，特别是黑色素瘤的方法。
• SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS
  申请人：H.LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US20150056213A1

  公开（公告）日：2015-02-26

  Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

  本发明涉及具有式(I)的选择性组蛋白去乙酰化酶抑制剂（HDACi）。本发明还公开了制备和使用这些抑制剂治疗癌症，特别是黑色素瘤的方法。
• Selective histone deactylase 6 inhibitors
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US10227295B2

  公开（公告）日：2019-03-12

  Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

  所公开的是具有式 I 的选择性组蛋白去乙酰化酶抑制剂（HDACi）。还公开了制造和使用这些抑制剂治疗癌症，特别是黑色素瘤的方法。
• PREPARATION AND USE OF BICYCLIC HIMBACINE DERIVATIVES AS PAR-RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2822557A1

  公开（公告）日：2015-01-14